Why Co-Diagnostics, Inc.’s (CODX) Stock Is Down 53.25%
As of Tuesday, October 28, Co-Diagnostics, Inc.’s CODX share price has dipped by 53.25%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. CODX
$1.46
-0.10
-6.41%
July 31, 2026 11:00:48 AM
EST
Volume: 238,991
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Commentary & Analysis
7 Undervalued Health Care Equipment & Supplies Stocks for Friday, October 18
Discover the top 7 undervalued Health Care Equipment & Supplies stocks for Friday, October 18 based on AAII’s Stock Grades.Omar Beirat
3 Undervalued Advanced Medical Equipment & Technology Stocks for Thursday, March 21
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Thursday, March 21 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Tuesday, February 13
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Tuesday, February 13 based on AAII’s Stock Grades.Jenna Brashear
3 Undervalued Advanced Medical Equipment & Technology Stocks for Monday, December 25
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Monday, December 25 based on AAII’s Stock Grades.Eunice Kim
Financial Summary
| Share Statistics | CODX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.7 | $334.8 | 4% |
|
| Shares Out (Mil) | 2.3 | 41.7 | 8% |
|
| Institutional Ownership | 77.8% | 77.3% | 48% |
|
| Float (Mil) | 3.5 | 34.7 | 9% |
|
| Beta | 2.85 | 0.86 | 97% |
|
| Avg Daily Volume (000s) | 457 | 266 | 58% |
|
| Price Change (52-week) |
(80.0%) | 60.7% | 7% |
|
| Growth | CODX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (61.9%) | 11.8% | 0% |
|
| Net Income (5yr) | (25.4%) | (5.8%) | 16% |
|
| EPS (5yr) | (22.6%) | 10.7% | 11 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (32.3%) | (16.1%) | 17% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($3.000) | ($13.500) | ($12.000) | |
| Month Ago EPS | ($3.000) | ($13.500) | ($12.000) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($3.000) | ($12.150) | ($12.000) | |
| Year/Year Chg | (26.1%) | (61.7%) | (80.4%) | |
| Financials | CODX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $152 | 1% |
|
| Net Income (TTM) (Mil) | ($49) | ($11) | 16% |
|
| EPS (TTM) | ($29.820) | ($0.500) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($2) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $1 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $22 | 18% |
|
| Enterprise Value (Q1) (Mil) | $3 | $304 | 5% |
|
| Valuation | CODX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.35 | 2.88 | 5% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | CODX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 45.1% | 59.1% | 56% |
|
| Net Margin | na | (7.7%) | na |
|
| ROA | (126.6%) | (13.7%) | 4% |
|
| ROE | (151.7%) | (15.9%) | 6% |
|
| Liabilities to Assets | 25.4% | 44.9% | 17% |
|
| F-Score | 1 | 4 | 1% |
|
Co-Diagnostics, Inc. did not pass any screens on 7/30/2026.
